Search research articles
Contact Us
Filters
Showing results (141-150 of 346) with videos related to
Page
of 35
Sort By:
American Journal of Hematology
|
September 2, 2025
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML
Sankalp Arora, Sanam Loghavi, Naval Daver, et al.
Leukemia
|
May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.
American Journal of Hematology
|
May 2, 2020
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin
Nicholas J Short, Guillaume Richard-Carpentier, Rashmi Kanagal-Shamanna, et al.
Cancer
|
March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
Alexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
Blood Advances
|
April 11, 2022
Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
Hussein A Abbas, Hanxiao Sun, Sherry Pierce, et al.
Journal of Hematology & Oncology
|
June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena, Elias Jabbour, Ghayas Issa, et al.
American Journal of Hematology
|
December 11, 2022
Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission
Oren Pasvolsky, Rima M Saliba, Celina Ledesma, et al.
American Journal of Hematology
|
February 27, 2021
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine
Kiyomi Morita, Nitin Jain, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.
Blood
|
October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
Elias Jabbour, Fadi G Haddad, Nicholas J Short, et al.
Page
of 35
Search research articles
Search
Showing results (141-150 of 346) with videos related to
Sort By:
Page
of 35
American Journal of Hematology
|
September 2, 2025
Cytomolecular Mechanisms of Relapse and Post-Relapse Outcomes After Frontline FLT3 Inhibitor-Based Therapy in FLT3-Mutated AML
Sankalp Arora, Sanam Loghavi, Naval Daver, et al.
Leukemia
|
May 3, 2023
Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRD
Philip A Thompson, Michael J Keating, Alessandra Ferrajoli, et al.
American Journal of Hematology
|
May 2, 2020
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin
Nicholas J Short, Guillaume Richard-Carpentier, Rashmi Kanagal-Shamanna, et al.
Cancer
|
March 18, 2025
A retrospective study of outcomes across time and treatment regimens in newly diagnosed, FMS-like tyrosine kinase 3 (FLT3)-mutated acute myeloid leukemia
Alexandre Bazinet, Alex Bataller, Tapan Kadia, et al.
Blood Advances
|
April 11, 2022
Validation of the ALFA-1200 model in older patients with AML treated with intensive chemotherapy
Hussein A Abbas, Hanxiao Sun, Sherry Pierce, et al.
Journal of Hematology & Oncology
|
June 16, 2021
Impact of frontline treatment approach on outcomes of myeloid blast phase CML
Kapil Saxena, Elias Jabbour, Ghayas Issa, et al.
American Journal of Hematology
|
December 11, 2022
Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission
Oren Pasvolsky, Rima M Saliba, Celina Ledesma, et al.
American Journal of Hematology
|
February 27, 2021
Outcome of T-cell acute lymphoblastic leukemia/lymphoma: Focus on near-ETP phenotype and differential impact of nelarabine
Kiyomi Morita, Nitin Jain, Hagop Kantarjian, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
February 10, 2020
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Guillaume Richard-Carpentier, Elias Jabbour, Nicholas J Short, et al.
Blood
|
October 25, 2023
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
Elias Jabbour, Fadi G Haddad, Nicholas J Short, et al.
Page
of 35